| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | 10% Owner | Director
21 companies
Redmile Group, LLC is a 10% Owner at ADCT with holdings across 21 companies. Recent SEC Form 4 filings include 16 buys and 0 sells.
Estimated insider holdings value: $702.4M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 2, 2020 | NGNE Neurogene Inc. | 10% Owner | Buy | 194,300 | $10.35 | $2,011,281.13 | +0.5% | |
| Oct 7, 2019 | APRE Aprea Therapeutics, Inc. | 10% Owner | Buy | 400,000 | $15.00 | $6,000,000.00 | +21.4% | |
| Sep 16, 2019 | FATE Fate Therapeutics Inc | Director, 10% Owner | Buy | 857,143 | $17.50 | $15,000,002.50 | +8.3% | |
| Sep 25, 2018 | FATE Fate Therapeutics Inc | Director, 10% Owner | Buy | 3,703,704 | $13.50 | $50,000,004.00 | +55.6% | |
| Jul 6, 2016 | SYRS Syros Pharmaceuticals, Inc. | 10% Owner | Buy | 432,746 | $12.50 | $5,409,325.00 | +113.5% |